Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11895791rdf:typepubmed:Citationlld:pubmed
pubmed-article:11895791lifeskim:mentionsumls-concept:C0679729lld:lifeskim
pubmed-article:11895791lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:11895791lifeskim:mentionsumls-concept:C1333782lld:lifeskim
pubmed-article:11895791lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:11895791lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:11895791lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:11895791pubmed:issue7lld:pubmed
pubmed-article:11895791pubmed:dateCreated2002-3-15lld:pubmed
pubmed-article:11895791pubmed:abstractTextGastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de l'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.lld:pubmed
pubmed-article:11895791pubmed:languageenglld:pubmed
pubmed-article:11895791pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11895791pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11895791pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11895791pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11895791pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11895791pubmed:statusMEDLINElld:pubmed
pubmed-article:11895791pubmed:monthAprlld:pubmed
pubmed-article:11895791pubmed:issn0006-4971lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:BathP EPElld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:CotterFinbarr...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:GiardiniRober...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:PonzoniMauril...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:CazzanigaGiov...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:BiondiAndreaAlld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:BertoniFrance...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:ConconiAnnari...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:CapellaCarloClld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:MottaTeresioTlld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:PedrinisEnnio...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:NoveroDomenic...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:RinaldiPaoloPlld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:WotherspoonAn...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:HancockBarry...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:SmithPaulPlld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:SouhamiRobert...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:CavalliFranco...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:ZuccaEmanuele...lld:pubmed
pubmed-article:11895791pubmed:authorpubmed-author:United...lld:pubmed
pubmed-article:11895791pubmed:issnTypePrintlld:pubmed
pubmed-article:11895791pubmed:day1lld:pubmed
pubmed-article:11895791pubmed:volume99lld:pubmed
pubmed-article:11895791pubmed:ownerNLMlld:pubmed
pubmed-article:11895791pubmed:authorsCompleteYlld:pubmed
pubmed-article:11895791pubmed:pagination2541-4lld:pubmed
pubmed-article:11895791pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:meshHeadingpubmed-meshheading:11895791...lld:pubmed
pubmed-article:11895791pubmed:year2002lld:pubmed
pubmed-article:11895791pubmed:articleTitleMolecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.lld:pubmed
pubmed-article:11895791pubmed:affiliationDepartment of Experimental Haematology, Barts and The London-Queen Mary's School of Medicine and Dentistry, London, United Kingdom. frbertoni@tin.itlld:pubmed
pubmed-article:11895791pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11895791pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11895791pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:11895791pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:11895791pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11895791lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11895791lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11895791lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11895791lld:pubmed